GSK’s new flu vaccine approved in US
The approval of FluLaval is an attempt to increase the influenza vaccine supply in the US. The approval of FluLaval follows the introduction of GSK's Fluarix prior to
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.